Country
Full text data for US and EP
Status
Type
Filing Date
Publication Date
Inventor
Assignee
Click to expand
IPC
No.
Publication Number
Title
Publication/Patent Number Publication/Patent Number
Publication date Publication date
Application number Application number
Filing date Filing date
Inventor Inventor
Assignee Assignee
IPC IPC
1
US20180214413A1
Publication/Patent Number: US20180214413A1
Publication date: 2018-08-02
Application number: 15/820,324
Filing date: 2017-11-21
Abstract: The present technology is directed to modulators of nuclear receptor activity, specifically to the modulation of NR2F6 activity and NR2F6 utilizing compounds, and the immune modulation and modulation of cancer stem cell activity through administration of compounds described herein to humans. The present technology is directed to modulators of nuclear receptor activity, specifically to the modulation of NR2F6 activity and NR2F6 utilizing compounds, and the immune modulation and modulation of cancer stem cell activity through administration of compounds described ...more ...less
2
US20180214418A1
Publication/Patent Number: US20180214418A1
Publication date: 2018-08-02
Application number: 15/937,475
Filing date: 2018-03-27
Abstract: There are provided inter alia multisubstituted aromatic compounds useful for the inhibition of thrombin, which compounds include substituted pyrazolyl or substituted triazolyl. There are additionally provided pharmaceutical compositions. There are additionally provided methods of treating and preventing a disease or disorder, which disease or disorder is amenable to treatment or prevention by the inhibition of thrombin. There are provided inter alia multisubstituted aromatic compounds useful for the inhibition of thrombin, which compounds include substituted pyrazolyl or substituted triazolyl. There are additionally provided pharmaceutical compositions. There are additionally provided methods ...more ...less
3
US20180214420A1
Publication/Patent Number: US20180214420A1
Publication date: 2018-08-02
Application number: 15/722,399
Filing date: 2017-10-02
Abstract: Disclosed herein are pharmaceutical compositions, methods and kits for lowering the serum uric acid level of a subject and for the treatment of a condition associated with elevated serum uric acid levels comprising administering a composition comprising a first urate-lowering agent and a second urate-lowering agent. In some aspects the first urate-lowering agent is (−)-halofenate, (−)-halofenic acid, or a pharmaceutically acceptable salts thereof. In some aspects the second urate-lowering agent is an inhibitor of uric acid production, a uricosuric agent, a uricase, or a pharmaceutically acceptable salt thereof. Disclosed herein are pharmaceutical compositions, methods and kits for lowering the serum uric acid level of a subject and for the treatment of a condition associated with elevated serum uric acid levels comprising administering a composition comprising a first urate-lowering ...more ...less
4
US20180214427A1
Publication/Patent Number: US20180214427A1
Publication date: 2018-08-02
Application number: 15/749,701
Filing date: 2016-08-03
Assignee: Samumed, LLC
Abstract: 6-Azaindazole compounds for treating various diseases and pathologies are disclosed. More particularly, the present disclosure concerns the use of a 6-azaindazole compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, fibrotic disorders, bone or cartilage diseases, and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as genetic diseases and neurological conditions/disorders/diseases due to mutations or dysregulation of the Wnt pathway and/or of one or more of Wnt signaling components. Also provided are methods for treating Wnt-related disease states. 6-Azaindazole compounds for treating various diseases and pathologies are disclosed. More particularly, the present disclosure concerns the use of a 6-azaindazole compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling ...more ...less
5
US20180214434A1
Publication/Patent Number: US20180214434A1
Publication date: 2018-08-02
Application number: 15/920,822
Filing date: 2018-03-14
Abstract: The instant invention relates to a semi-solid topical composition containing Pirfenidone and an antimicrobial/antiseptic agent such as Modified Diallyl Disulfide Oxide (M-DDO) and its preparation process, offering advantages compared to other pharmaceutical forms of topical administration known in the state of the art, useful as antifibrotic, anti-inflammatory and antiseptic agent in the prevention, treatment and reversion of acne and post acne lesions. Said compositions is also useful for reducing skin redness, detaining the formation of new acne outbreaks, reversing already existing outbreaks and regenerating skin damage caused by acne. The instant invention relates to a semi-solid topical composition containing Pirfenidone and an antimicrobial/antiseptic agent such as Modified Diallyl Disulfide Oxide (M-DDO) and its preparation process, offering advantages compared to other pharmaceutical forms of topical ...more ...less
6
US20180214436A1
Publication/Patent Number: US20180214436A1
Publication date: 2018-08-02
Application number: 15/913,481
Filing date: 2018-03-06
Assignee: NLS PHARMA AG
Abstract: The invention relates to the treatment of an attention deficit hyperactivity disorder (ADHD) with alpha-phenyl(piperidin-2-yl)methanol, or the pharmaceutically acceptable salts and esters thereof, in particular the acetate derivative, more particularly dextrophacetoperane. The invention additionally provides a method of synthesis of the (S,S) enantiomer of alpha-phenyl(piperidin-2-yl)methanol as well as a method of synthesis of dextrophacetoperane. The invention relates to the treatment of an attention deficit hyperactivity disorder (ADHD) with alpha-phenyl(piperidin-2-yl)methanol, or the pharmaceutically acceptable salts and esters thereof, in particular the acetate derivative, more particularly dextrophacetoperane. The ...more ...less
7
US20180214439A1
Publication/Patent Number: US20180214439A1
Publication date: 2018-08-02
Application number: 15/745,838
Filing date: 2016-07-27
Abstract: The present invention is directed to azacyanoquinolinone compounds which may be useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 9 (PDE9). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction. The present invention is directed to azacyanoquinolinone compounds which may be useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 9 (PDE9). The present invention also relates to the use of such compounds for ...more ...less
8
US20180214441A1
Publication/Patent Number: US20180214441A1
Publication date: 2018-08-02
Application number: 15/895,783
Filing date: 2018-02-13
Abstract: Disclosed is the synthesis procedure for benzazolo[3,2-a]quinolinium chloride salts and the inclusion of chloro-substituent, amino-substituent, and nitro-substituent resulting in several compounds. The compounds are further used as markers due to their fluorescent properties including in hypoxic environments. This disclosure further describes anti-cancer screening of two BQS, namely, 7-benzyl-3-aminobenzimidazo[3,2-a]quinolinium chloride (ABQ-48: NSC D-763307) and the corresponding 7-benzyl-3-nitrobenzimidazo[3,2-a]quinolinium chloride (NBQ 48: NSC D-763303). Disclosed is the synthesis procedure for benzazolo[3,2-a]quinolinium chloride salts and the inclusion of chloro-substituent, amino-substituent, and nitro-substituent resulting in several compounds. The compounds are further used as markers due to their fluorescent properties ...more ...less
9
US20180214444A1
Publication/Patent Number: US20180214444A1
Publication date: 2018-08-02
Application number: 15/799,520
Filing date: 2017-10-31
Abstract: The present invention provides a heterocyclic compound represented by the general formula (1): The compound of the present invention has a wide treatment spectrum for mental disorders including central nervous system disorders, no side effects and high safety.
10
US20180214449A1
Publication/Patent Number: US20180214449A1
Publication date: 2018-08-02
Application number: 15/746,206
Filing date: 2016-01-28
Assignee: UBRX, INC.
Abstract: Provided herein are new therapeutic regimens for treatment of cancer with a combination of a JAK inhibitor and an inhibitor targeting the MAPK pathway, combinations and methods of use thereof. In some embodiments, described herein are methods for treating cancer in an individual in need thereof, comprising administration of a JAK inhibitor and an inhibitor targeting the MAPK pathway to the individual. In some embodiments, the JAK inhibitor is a JAKI inhibitor. Provided herein are new therapeutic regimens for treatment of cancer with a combination of a JAK inhibitor and an inhibitor targeting the MAPK pathway, combinations and methods of use thereof. In some embodiments, described herein are methods for treating cancer in an individual ...more ...less
11
US20180214451A1
Publication/Patent Number: US20180214451A1
Publication date: 2018-08-02
Application number: 15/936,659
Filing date: 2018-03-27
Assignee: Novartis AG
Abstract: The present invention relates to a method of treating cancer in a human and to pharmaceutical combinations useful in such treatment. In particular, the method relates to a cancer treatment method that includes administering N-{3-[3-cyclopropyl-5-(2-fluoro-4-iodo-phenylamino)-6,8-dimethyl-2,4,7-trioxo-3,4,6.7-tetrahydro-2H-pyrido[4,3-d]pyrimidin-1-yl]phenyl}acetamide, or a pharmaceutically acceptable salt or solvate thereof, and N-[(1S)-2-amino-1-[(3-fluorophenyl)methyl]ethyl]-5-chloro-4-(4-chloro-1-methyl-1H-pyrazol-5-yl)-2-thiophenecarboxamide, or a pharmaceutically acceptable salt thereof, to a human in need thereof. The present invention relates to a method of treating cancer in a human and to pharmaceutical combinations useful in such treatment. In particular, the method relates to a cancer treatment method that includes administering ...more ...less
12
US20180214453A1
Publication/Patent Number: US20180214453A1
Publication date: 2018-08-02
Application number: 15/742,166
Filing date: 2016-08-04
Abstract: A rivaroxaban immediate release tablet comprising a non-ionic surfactant obtainable by using a dry process (i.e. no solvent is used during the manufacturing of the core tablet) which rapidly releases the drug as well as shows high stability and its fast and fed bioavailability is only attributable to the rivaroxaban behaviour. A rivaroxaban immediate release tablet comprising a non-ionic surfactant obtainable by using a dry process (i.e. no solvent is used during the manufacturing of the core tablet) which rapidly releases the drug as well as shows high stability and its fast and fed bioavailability ...more ...less
13
US20180214454A1
Publication/Patent Number: US20180214454A1
Publication date: 2018-08-02
Application number: 15/886,807
Filing date: 2018-02-01
Inventor: Ahee, Jason  
Assignee: Ahee, Jason
Abstract: A method of preventing post-operative endophthalmitis involves injecting an antibiotic solution into the anterior segment of the eye during surgery, the antibiotic solution having moxifloxacin, cefuroxime, vancomycin, or some combination thereof.
14
US20180214463A1
Publication/Patent Number: US20180214463A1
Publication date: 2018-08-02
Application number: 15/742,996
Filing date: 2016-07-08
Abstract: The invention relates to the use of phytate or any of the salts thereof for preventing the formation of advanced glycation end-products (AGE), toxic products that are produced in pathologies such as diabetes, either alone or combined with B6 vitamins such as pyridoxamine and forming part of a medicament or a pharmaceutical composition produced so as to be administered via oral, rectal, subcutaneous, intra-arterial, intramuscular, intraspinal, intracranial, intravenous or inhalation routes. The invention relates to the use of phytate or any of the salts thereof for preventing the formation of advanced glycation end-products (AGE), toxic products that are produced in pathologies such as diabetes, either alone or combined with B6 vitamins such as pyridoxamine and ...more ...less
15
US20180214465A1
Publication/Patent Number: US20180214465A1
Publication date: 2018-08-02
Application number: 15/935,782
Filing date: 2018-03-26
Inventor: